VISIGALLI, DEBORA
VISIGALLI, DEBORA
Universita' degli Studi di MILANO
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025
2025 D. Moschese, R. Esvan, C. Fusetti, V. Barchi, M.V. Cossu, A. Giacinta, S. Lazzarin, G. Terracini, F. Caruso, G. Micheli, D. Maddalena, G. Del Duca, F. Petri, G. Frate, M. Matone, D. Farinacci, A. Giacomelli, P. Faccendini, D. Visigalli, S. Passacantilli, A. Riva, A. Antinori, A. Gori, V. Mazzotta
Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease
2024 M. Colaneri, G. Scaglione, F. Fassio, L. Galli, A. Lai, A. Bergna, A. Gabrieli, M. Tarkowski, C.D. Ventura, V. Colombo, L. Cordier, D. Bernasconi, M. Corbellino, G. Dedivitiis, S. Borghetti, D. Visigalli, S. Sollima, G. Casalini, G. Rizzardini, A. Gori, S. Antinori, A. Riva, M. Schiavini
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency
2022 A. Zanichelli, V. Montinaro, M. Triggiani, F. Arcoleo, D. Visigalli, M. Cancian